Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 hyperimmune globulin
- Development stage
- Discontinued
- Lead developer
- University of Melbourne
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
COVID-19 hyperimmune globulin (University of Melbourne) is a biologic therapy composed of polyclonal antibodies concentrated from the convalescent plasma of individuals who have recovered from SARS-CoV-2 infection. It is designed to provide passive immunotherapy by delivering a high concentration of neutralizing antibodies that target the SARS-CoV-2 virus, thereby inhibiting viral replication and reducing disease severity in hospitalized patients. This specific product was slated for investigation in the Domain B (antibody domain) of the ASCOT (Australasian COVID-19 Trial) adaptive platform trial, though the arm was ultimately never opened for enrollment.
- Other names
- COVID-19 Hyper-Immunoglobulin (Human)hyperimmune globulin
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on COVID-19 hyperimmune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 hyperimmune globulin.